T1	p 178 197	diabetic patients :
T2	p 678 728	360 diabetic patients with coronary artery disease
T3	p 2559 2607	diabetic patients with coronary artery disease .
T4	i 119 131	pioglitazone
T5	i 228 240	Pioglitazone
T6	i 451 463	pioglitazone
T7	i 628 639	glimepiride
T8	i 747 774	pioglitazone or glimepiride
T9	i 808 820	Pioglitazone
T10	i 1568 1580	pioglitazone
T11	i 1758 1769	glimepiride
T12	i 2356 2368	pioglitazone
T13	o 925 954	Coronary atheroma progression
T14	o 1067 1118	percent atheroma volume , and total atheroma volume
T15	o 1207 1337	in high-density lipoprotein cholesterol ( HDL-C ) and reductions in glycated hemoglobin , triglycerides , and C-reactive protein .
T16	o 1396 1437	percent atheroma volume and triglycerides
T17	o 1464 1488	triglyceride/HDL-C ratio
T18	o 1519 1538	glycated hemoglobin
T19	o 1598 1633	low-density lipoprotein cholesterol
T20	o 1784 1803	atheroma regression
T21	o 1944 1957	triglycerides
T22	o 1995 2019	triglyceride/HDL-C ratio
T23	o 2070 2089	glycated hemoglobin
T24	o 2245 2268	percent atheroma volume
T25	o 2286 2307	total atheroma volume
T26	o 2425 2445	atheroma progression